Where Global Innovation
and Capital Meet
Sectors Consumer University Energy Financial Healthcare Industrial IT Media Services Telecoms Transport The Art of CVC Startups

Page 279

Codiak loads up IPO filing

Alexandria Real Estate Equities-backed exosome therapeutics developer Codiak BioSciences is eyeing up to $86.3m in a forthcoming IPO.

May 2, 2019

Vividion wins $82m in series B round

The immuno-oncology therapy developer received funding from investors including Alexandria Real Estate Equities and strategic collaborator Celgene.

May 2, 2019

Symic Bio secures $11m

The Eli Lilly and Mitsui-backed drug developer has received $11m in a round led by Cell Innovation Partners, taking its overall funding to more than $83m.

May 1, 2019

LinkedCare registers series C1 funding

Taikang Life Insurance backed a $14.8m round for the online medical data platform, which already counts Fosun, DXY and Meituan Dianping as shareholders.

May 1, 2019

908 Devices calls on corprorates for series E round

908 Devices plans to add a life science device to its chemical detection product range, having landed $17.5m in a Schlumberger and Saudi Aramco-backed round.

May 1, 2019

CPSI seeks out Get Real Health for acquisition

Telus Ventures is set to exit healthcare data management software producer Get Real Health in an $11m purchase by CPSI, six years after it invested.

May 1, 2019

MRCF impresses with $148m for fifth fund

MRCF has reached the first close of a CSL-backed fifth fund to make early-stage investments in medical technologies in Australia and New Zealand.

May 1, 2019

Congenica coaxes DC Health for series B extension

Digital China Health Technologies chipped into the third tranche of a round featuring fellow corporates BGI Genomics and Healthlink that now tops $30m.

May 1, 2019

Ideaya identifies Nasdaq for $70m IPO

Alphabet, WuXi AppTec, Celgene, Roche and Novartis are in line to exit precision oncology therapy developer Ideaya Biosciences, which has filed to go public.

May 1, 2019

Bicycle Therapeutics to go for a spin on Nasdaq

Astellas, Novartis and GlaxoSmithKline are in line for exits as oncology drug developer Bicycle Therapeutics prepares to float, having filed to raise $86m in its IPO.

Apr 30, 2019
© 2024 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here